智通财经APP获悉，周一，诺和诺德(NVO.US)开盘跌超8%，报80.10美元。消息面上，数据显示诺和诺德的Cagrisema在68周后(使患者)体重减轻15.7%，市场原本预期是20%，相比之下，安慰剂组的体重减轻了3.1%。诺和诺德预计将在2026年第一季度申请CagriSema的首个监管批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.